Department of Dermatology, Ghent University Hospital, Ghent, Belgium.
Department of Dermatology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.
Acta Clin Belg. 2024 Feb;79(1):62-74. doi: 10.1080/17843286.2023.2285576. Epub 2024 Jan 2.
Atopic dermatitis (AD) is one of the most common, bothersome and difficult to treat skin disorders. Recent introduction of new systemic treatments has revolutionized the management of AD. The goal of this guideline is to provide evidence-based recommendations for the management of patients suffering from atopic dermatitis that easily can be implemented in clinical practice. These recommendations were developed by 11 Belgian AD experts. Comments of all experts on the proposed statements were gathered, followed by an online voting session. The most relevant strategies for the management and treatment of AD in the context of the Belgian health care landscape are discussed. General measures, patient education and adequate topical treatment remain the cornerstones of AD management. For moderate to severe AD, the introduction of biologics and JAK inhibitors show unprecedented efficacy, although currently access is limited to a subgroup of patients meeting the reimbursement criteria.
特应性皮炎（AD）是最常见、最令人困扰且最难治疗的皮肤疾病之一。最近新的系统治疗方法的出现彻底改变了 AD 的治疗管理模式。本指南的目的是为患有特应性皮炎的患者提供基于证据的管理建议，以便于在临床实践中实施。这些建议是由 11 位比利时 AD 专家制定的。收集了所有专家对拟议声明的意见，并随后进行了在线投票。讨论了在比利时医疗保健背景下管理和治疗 AD 的最相关策略。一般措施、患者教育和适当的局部治疗仍然是 AD 管理的基石。对于中重度 AD，生物制剂和 JAK 抑制剂的引入显示出前所未有的疗效，尽管目前仅限于符合报销标准的亚组患者。
